New research reveals that people who come off new slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional diet and exercise plans.
Published data in a major medical journal points out that while overweight individuals often shed a large proportion of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Users using these treatments must be cognizant of the potential of rapid weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass in about 18 months.
Analyzing Treatments
The analysis, which reviewed 37 of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through dieting usually have a slower weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Experts propose the way of the drugs explains the amplified rebound.
These medications mimic a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means appetite is unsuppressed, making overeating much more probable."
A Chronic Condition?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals argue that, given the high risk of relapse, the therapy might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "emphasize the chronic nature of obesity," akin to managing diseases like hypertension.
User Experiences
Users who have discontinued the medication explain a sudden return of hunger.
"It felt as if a switch flipping and you're instantly starving," recalled an individual.
This challenge is worsened if users have not developed lasting lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a magic fix and maintained weight loss relies on ongoing lifestyle management.
